HLUN-B.CO vs. NVO

In the year-to-date period, HLUN-B.CO achieves a 1.50% return, which is significantly higher than NVO's -9.47% return. Over the past 10 years, HLUN-B.CO has underperformed NVO with an annualized return of 5.35%, while NVO has yielded a comparatively higher 15.51% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for H Lundbeck A/S (HLUN-B.CO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HLUN-B.CO Sharpe Ratio is 1.32, which is higher than the NVO Sharpe Ratio of -0.92. The chart below compares the historical Sharpe Ratios of HLUN-B.CO and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

HLUN-B.CO's dividend yield for the trailing twelve months is around 1.67%, less than NVO's 1.85% yield.

The maximum HLUN-B.CO drawdown since its inception was -91.40%, which is greater than NVO's maximum drawdown of -71.32%. Use the drawdown chart below to compare losses from any high point for HLUN-B.CO and NVO. For additional features, visit the drawdowns tool.

The current volatility for H Lundbeck A/S (HLUN-B.CO) is 9.43%, while Novo Nordisk A/S (NVO) has a volatility of 13.24%. This indicates that HLUN-B.CO experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between H Lundbeck A/S and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.